• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Carbon nanotube delivery of siRNAs could prevent kidney injury [PreClinical]

byChristine YoonandJessica Lau
April 4, 2016
in Chronic Disease, Nephrology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Ammonium-functionalized carbon nanotubes (fCNTs) that delivered small interfering RNAs (siRNAs) to the kidney were able to suppress expression of two target genes involved in acute kidney injury (AKI).

2. In a mouse model of AKI, fCNTs loaded with siRNAs enhanced progression-free survival and reduced fibrosis and immune infiltration of the kidney.

Evidence Rating Level: 2 (Good)           

Study Rundown: AKI, a common and deadly side effect of medical regimens like chemotherapy, currently lacks preventative and therapeutic treatments. In this work, the authors developed a prophylactic therapy for AKI by exploiting the ability for fibrillar fCNTs to carry siRNA cargo and traffic to the kidney.

In an initial test of siRNA delivery, fCNTs carrying siTrp53 or siMep1b (siRNAs targeting the p53 and meprin-1β proteins, respectively) were injected into mice for 3 consecutive days. Histological analysis of cortical kidney sections demonstrated reduced expression of p53 and meprin-1β in mice with fCNT/siRNA treatment as compared to those treated with saline or siRNA alone. To test prophylactic efficacy in a model of AKI, mice were treated with fCNTs loaded with siTrp53 and siMep1b before receiving a nephrotoxic dose of the chemotherapy drug cisplatin. Compared to the control group that received fCNT with a control siRNA, mice treated with fCNT/siTrp53/siMep1b had near normal kidney levels of p53 and meprin-1β. Treatment with fCNT/siTrp53/siMep1b also led to greater survival rates of mice for 11 days after cisplatin injury and reduced kidney fibrosis at 6 months after injury. Tissue staining for immune cells showed decreased acute and chronic immune infiltration in fCNT/siTrp53/siMep1b mice versus control mice, at 11 days and 6 months post-injury.

Overall, this study describes a novel treatment paradigm for preventing drug-induced AKI. While some general safety studies were completed in this work, more comprehensive analyses of fCNT biocompatibility and potential off-target effects are necessary before transition to clinical trials. If successful, this treatment approach could also relieve clinical drug dosage limitations due to deleterious AKI responses.

Click to read the study in Science Translational Medicine

RELATED REPORTS

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

Relevant Reading: Activation and involvement of p53 in cisplatin-induced nephrotoxicity

In-Depth [animal study]: Healthy female Balb/c mice received daily intravenous injections of fCNT/siTrp53 or fCNT/siMep1b (0.032mg at 1:1 molar ratio), siTrp53 or siMep1b alone (0.002mg each), or PBS control for 3 consecutive days. On day 4, the kidneys were harvested and sectioned for immunohistochemistry (n=3). Staining for p53 and meprin-1β  showed that delivery of siRNA with fCNTs significantly decreased the portion of p53- and meprin-1β-positive tissue, thus demonstrating improved suppression of target genes over PBS or siRNA alone controls (p<0.0001).

In the AKI model, mice were treated with fCNT/siRNA for 5 days, with cisplatin injury induced on day 3 via a 10mg/kg dose. fCNT/siTrp53/siMep1b and the control fCNT/siScram were each administered at 1.6mg fCNT + 0.087mg siRNA/kilogram. Kidneys were harvested on day 6, and histology revealed lower expression of both proteins with the fCNT/ siTrp53/siMep1b treatment versus control. The two protein levels in fCNT/siTrp53/siMep1b-treated animals were decreased to near normal concentrations, as determined by enzyme-linked immunosorbent assay results of homogenized kidney tissue (n=3-4). Progression-free survival of injured mice treated with fCNT/ siTrp53/siMep1b was 88% over the 11 days after cisplatin administration, higher than that of all other control groups (including delivery of siRNAs alone). Picrosirius red staining of kidney cortex slices demonstrated a significant reduction of fibrotic tissue formation in fCNT/ siTrp53/siMep1b mice 180 days after injury (p=0.0397). At 11 and 180 days post-injury, fCNT/ siTrp53/siMep1b treatment significantly decreased the density of immune cells in the kidney, as measured by immunostaining for CD3+ T cells, CD45+ lymphocytes, and Iba1+ macrophages (p<0.0059, n=6-9).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Greatest reduction in pregnancy occurs with any contraception

Next Post

Estradiol may be anti-atherosclerotic in early postmenopausal women: the ELITE study

RelatedReports

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

June 29, 2022
Novel combination therapy may be effective for noncirrhotic HCV infection [UNITY-1 trial]
Chronic Disease

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

June 29, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

June 29, 2022
#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Anti-tau antibody Semorinemab not shown to slow clinical progression of Alzheimer’s disease

June 29, 2022
Next Post
PCSK9 antibodies safe and effective in treating dyslipidemia

Estradiol may be anti-atherosclerotic in early postmenopausal women: the ELITE study

Increasing survival rates for patients with acute liver failure

Increasing survival rates for patients with acute liver failure

Vitamin D supplementation amongst post-menopausal women did not improve functional outcomes

Parathyroidectomy associated with increased bone mineral density and decreased fracture rate in patients with primary hyperparathyroidism

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.